KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Change in Accured Expenses (2016 - 2026)

Palvella Therapeutics has reported Change in Accured Expenses over the past 5 years, most recently at $1.0 million for Q4 2017.

  • Quarterly Change in Accured Expenses rose 9.71% to $1.0 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2017, changed 0.15% year-over-year, with the annual reading at -$1.3 million for FY2025, 223.81% down from the prior year.
  • Change in Accured Expenses was $1.0 million for Q4 2017 at Palvella Therapeutics, up from -$1.3 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $3.1 million in Q2 2017 and troughed at -$1.3 million in Q3 2017.
  • The 5-year median for Change in Accured Expenses is $37871.0 (2016), against an average of $199871.4.
  • Year-over-year, Change in Accured Expenses crashed 36153.76% in 2014 and then soared 8188.21% in 2017.
  • A 5-year view of Change in Accured Expenses shows it stood at $1250.0 in 2013, then crashed by 36153.76% to -$450672.0 in 2014, then surged by 181.16% to $365748.0 in 2015, then skyrocketed by 152.62% to $923955.0 in 2016, then increased by 9.71% to $1.0 million in 2017.
  • Per Business Quant, the three most recent readings for PVLA's Change in Accured Expenses are $1.0 million (Q4 2017), -$1.3 million (Q3 2017), and $3.1 million (Q2 2017).